Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's Chief Financial & Business Officer, Bart van Rhijn, will participate in a fireside chat on Tuesday, May 20, 2025, at 5:00 pm EDT in New York. The presentation will be webcast live and available for replay on the company's investor relations website.
Nanobiotix (NASDAQ: NBTX), un'azienda biotecnologica in fase clinica avanzata specializzata in trattamenti oncologici a base di nanoparticelle, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale BioConnect per Investitori di H.C. Wainwright presso il NASDAQ. Il Chief Financial & Business Officer dell'azienda, Bart van Rhijn, prenderà parte a una conversazione informale il martedì 20 maggio 2025 alle 17:00 EDT a New York. La presentazione sarà trasmessa in diretta streaming e sarà disponibile per la visione on demand sul sito web delle relazioni con gli investitori dell'azienda.
Nanobiotix (NASDAQ: NBTX), una empresa biotecnológica en etapa clínica avanzada enfocada en tratamientos contra el cáncer basados en nanopartículas, anunció su participación en la 3ª Conferencia Anual BioConnect para Inversionistas de H.C. Wainwright en NASDAQ. El Director Financiero y de Negocios de la compañía, Bart van Rhijn, participará en una charla informal el martes 20 de mayo de 2025 a las 5:00 pm EDT en Nueva York. La presentación será transmitida en vivo por internet y estará disponible para su reproducción en el sitio web de relaciones con inversionistas de la empresa.
Nanobiotix (NASDAQ: NBTX)는 나노입자 기반 암 치료에 중점을 둔 후기 임상 단계의 생명공학 회사로, NASDAQ에서 열리는 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사의 최고재무책임자 겸 사업책임자인 Bart van Rhijn이 2025년 5월 20일 화요일 오후 5시(EDT) 뉴욕에서 열리는 파이어사이드 채팅에 참여할 예정입니다. 발표는 실시간 웹캐스트로 중계되며 회사의 투자자 관계 웹사이트에서 다시보기로 제공됩니다.
Nanobiotix (NASDAQ : NBTX), une société biotechnologique en phase clinique avancée spécialisée dans les traitements du cancer à base de nanoparticules, a annoncé sa participation à la 3e Conférence Annuelle BioConnect pour Investisseurs de H.C. Wainwright au NASDAQ. Le Directeur Financier et des Affaires de la société, Bart van Rhijn, participera à une discussion informelle le mardi 20 mai 2025 à 17h00 EDT à New York. La présentation sera diffusée en direct sur le web et disponible en replay sur le site des relations investisseurs de la société.
Nanobiotix (NASDAQ: NBTX), ein Biotechnologieunternehmen in der späten klinischen Phase, das sich auf nanopartikelbasierte Krebsbehandlungen spezialisiert hat, gab seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright am NASDAQ bekannt. Der Finanz- und Geschäftsdirektor des Unternehmens, Bart van Rhijn, wird an einem Gespräch am Kamin am Dienstag, den 20. Mai 2025, um 17:00 Uhr EDT in New York teilnehmen. Die Präsentation wird live im Webcast übertragen und auf der Investor-Relations-Website des Unternehmens zur Wiederholung verfügbar sein.
- None.
- None.
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Date: Tuesday, May 20, 2025
Time: 5:00 pm EDT / 11:00 pm CEST
Location: New York, NY
Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here
The fireside chats will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter
Contacts
| Nanobiotix | ||||
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Ricky Bhajun Director, Investor Relations +33 (0)6 42 05 34 15 investors@nanobiotix.com | |||
| Media Relations | ||||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com | |||
Attachments
FAQ
When is Nanobiotix (NBTX) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will represent Nanobiotix (NBTX) at the H.C. Wainwright Conference 2025?
What type of company is Nanobiotix (NBTX)?
How can investors watch Nanobiotix's (NBTX) presentation at the H.C. Wainwright Conference?
